Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can two simple questionnaires capture how bad sinus disease feels?

NCT ID NCT06970977

Diagnosis Sponsor: The European Forum for Research and Education in Allergy and Airway Diseases Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 09, 2026 · Last updated Sep 10, 2026 · Updated 1 time

Summary

Researchers at 32 medical centers in Europe, the USA, and South Africa are testing two new questionnaires designed to measure how severe chronic rhinosinusitis feels and how well it is controlled. About 1,000 patients with chronic rhinosinusitis, with or without nasal polyps, fill out the new questionnaires along with existing tools such as SNOT-22 and VAS scores during a routine ear, nose, and throat visit. The study compares the answers to see whether the new questionnaires match established measures and work across different languages. The goal is to validate a standard way to track this condition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
two new questionnaires for measuring chronic rhinosinusitis severity and control
What this could lead to
If the questionnaires hold up, doctors could gain a standard way to measure how severe chronic rhinosinusitis feels and how well it is controlled, which may help guide treatment decisions.
What could go wrong
This study tests a measurement tool, not a treatment, so it will not cure or ease the disease itself. A questionnaire can perform well in a study and still prove less useful in everyday practice, and results may differ across languages.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2024

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients, capable of giving consent, with certified CRS and no recent sinus surgery

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient capable of giving informed consent * Diagnosis of chronic rhinosinusitis with or without nasal polyposis according to the EPOS guidelines * No recent sinus surgery (within the last three months) Exclusion Criteria: * Not capable of giving informed consent * No CRS * Recent sinus surgery (within the last three months)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic rhinosinusitis (CRS) with and without nasal polyps are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic rhinosinusitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic rhinosinusitis (CRS) with and without nasal polyps

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    32 sites in 11 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ahmed Alkhadi Hospital

    RECRUITING

    Durban, South Africa

  • Alrijne Zorggroep

    RECRUITING

    Leiden, Netherlands

  • Brigham Sinus Center at Brigham and Women's Hospital

    RECRUITING

    Boston, Massachusetts, 02115, United States

  • Eastern Virginia Medical School

    RECRUITING

    Virginia City, Virginia, 23507, United States

  • HNO-Klinik, Universitätsklinikum Düsseldorf

    NOT_YET_RECRUITING

    Düsseldorf, Germany

  • Hospital Clinic Barcelona

    RECRUITING

    Barcelona, Spain

  • Hospital Clínico Universitario de Compostela

    RECRUITING

    A Coruña, Spain

  • Hospital General Universitario de Valencia

    RECRUITING

    Valencia, Spain

  • Hospital Universitario Fuenlabrada

    RECRUITING

    Madrid, Spain

  • Hospital Universitario Infanta Elena, Madrid y Hospital Universitario Fundación Jiménez Díaz

    RECRUITING

    Madrid, Spain

  • Hospital Universitario Jerez de La Frontera

    RECRUITING

    Cadiz, Spain

  • Hospital Universitario Marqués de Valdecilla

    RECRUITING

    Santander, Spain

  • Hospital Universitario Puerta del Mar

    RECRUITING

    Cadiz, Spain

  • Hospital Universitario Puerto Real

    RECRUITING

    Cadiz, Spain

  • Hospital Universitario Ramón y Cajal

    RECRUITING

    Madrid, Spain

  • Hospital Universitario Virgen Macarena

    RECRUITING

    Seville, Spain

  • Hospital de La Línea de La Concepción

    RECRUITING

    Cadiz, Spain

  • Hospital de la Santa Creu i Sant Pau

    RECRUITING

    Barcelona, Spain

  • Hospital del Bierzo

    RECRUITING

    Ponferrada, Spain

  • Northwestern University Feinberg School of Medicine

    RECRUITING

    Chicago, Illinois, 60208, United States

  • St. Michael's Hospital

    RECRUITING

    Toronto, Canada

  • Thomas Jefferson University Hospital

    RECRUITING

    Philadelphia, Pennsylvania, 19107, United States

  • U. Aristotle

    RECRUITING

    Thessaloniki, Greece

  • UCLA Santa Monica Medical Center

    RECRUITING

    Santa Monica, California, 90401, United States

  • UZ Gent

    NOT_YET_RECRUITING

    Ghent, Belgium

  • UZ Leuven

    RECRUITING

    Leuven, Belgium

  • Univ Amsterdam

    NOT_YET_RECRUITING

    Amsterdam, Netherlands

  • Univ Hospital Roma

    RECRUITING

    Roma, Italy

  • Univ Munich

    NOT_YET_RECRUITING

    Munich, Germany

  • Univ of Copenhagen

    RECRUITING

    Copenhagen, Denmark

  • University General Hospital of Heraklion

    RECRUITING

    Heraklion, Greece

  • University of Oradea

    RECRUITING

    Oradea, Romania

More trials for these conditions

Other studies related to the condition(s) this trial covers.